Phaseline

Targets › EGLN2

EGLN2 (Prolyl hydroxylase EGLN2): drug programs, companies and trials

4 programs from 4 companies in 8 trials: 3 Phase 3, 2 Phase 4, 2 Phase 1, 1 Phase 2; Genitourinary, Hematology, Psychiatry; next expected readout Oct 2027.

Prolyl hydroxylase that mediates hydroxylation of proline residues in target proteins, such as ATF4, IKBKB, CEP192 and HIF1A. Target proteins are preferentially recognized via a LXXLAP motif. Cellular oxygen sensor that catalyzes, under normoxic conditions, the post-translational formation of 4-hydroxyproline in hypoxia-inducible factor (HIF) alpha proteins. (UniProt, Q96KS0)

Open in Phaseline: the race on EGLN2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Zydus LifesciencesDesidustat
PHD inhibitor
EGLN1, EGLN2, EGLN3Phase 4Chronic Kidney Diseases–
AstellasRoxadustat
Hypoxia-inducible factor prolyl hydroxylase inhibitor
EGLN2, P4HTM, EGLN1, EGLN3Phase 3Chronic Kidney Disease; Dialysis; Complications; Perioperative Anemia; Kidney Failure, Chronic …Oct 2027
USRC Kidney ResearchVadadustat
Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor
EGLN1, EGLN3, EGLN2Phase 3Anemia of Chronic Kidney Disease–
Paul PotnuruVadadustat
Egl nine homolog 1 inhibitor; Egl nine homolog 3 inhibitor; Hypoxia-inducible factor prolyl hydroxylase 1 inhibitor
EGLN1, EGLN3, EGLN2Phase 2Nonintubated Acute Respiratory Distress Syndrome (ARDS)May 2031

Conditions

Chronic Kidney Disease (1) Dialysis; Complications (1) Perioperative Anemia (1) Kidney Failure, Chronic (1) Kidney Failure,Chronic (1) Anemia of Chronic Kidney Disease (1) Chronic Kidney Diseases (1) Nonintubated Acute Respiratory Distress Syndrome (ARDS) (1)

Modalities

small molecule (3), mixed (1)

Companies

Astellas (1) USRC Kidney Research (1) Zydus Lifesciences (1) Paul Potnuru (1)

Related targets

EGLN1 (4) EGLN3 (4) P4HTM (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.